Mohammad Azab

1.2k total citations
19 papers, 543 citations indexed

About

Mohammad Azab is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mohammad Azab has authored 19 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 10 papers in Molecular Biology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mohammad Azab's work include Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (5 papers) and Histone Deacetylase Inhibitors Research (5 papers). Mohammad Azab is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (5 papers) and Histone Deacetylase Inhibitors Research (5 papers). Mohammad Azab collaborates with scholars based in United States, Canada and United Kingdom. Mohammad Azab's co-authors include Aram Oganesian, Elizabeth A. Griffiths, Hagop M. Kantarjian, Gail J. Roboz, Karen Yee, Casey L. O’Connell, Wendy Stock, Pietro Taverna, James N. Lowder and David A. Rizzieri and has published in prestigious journals such as Blood, Cancer and Cancer Research.

In The Last Decade

Mohammad Azab

18 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mohammad Azab United States	10	367	309	87	69	62	19	543
Yu Jing China	15	301 0.8×	443 1.4×	127 1.5×	102 1.5×	39 0.6×	74	667
Harish G. Ahuja United States	11	406 1.1×	239 0.8×	60 0.7×	101 1.5×	100 1.6×	20	648
Tracy Murphy Canada	10	248 0.7×	265 0.9×	68 0.8×	55 0.8×	17 0.3×	29	463
Qitian Mu China	11	209 0.6×	127 0.4×	62 0.7×	33 0.5×	40 0.6×	61	370
Hyewon Lee South Korea	12	127 0.3×	220 0.7×	88 1.0×	46 0.7×	31 0.5×	38	424
Michele Cedrone Italy	16	296 0.8×	375 1.2×	237 2.7×	103 1.5×	24 0.4×	36	620
Naomi Kawashima Japan	8	129 0.4×	260 0.8×	75 0.9×	36 0.5×	34 0.5×	37	369
Giovanni Marconi Italy	10	166 0.5×	199 0.6×	61 0.7×	53 0.8×	20 0.3×	58	360
Hiroyoshi Kunimoto Japan	9	183 0.5×	205 0.7×	93 1.1×	14 0.2×	70 1.1×	23	425

Countries citing papers authored by Mohammad Azab

Since Specialization

Citations

This map shows the geographic impact of Mohammad Azab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Azab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Azab more than expected).

Fields of papers citing papers by Mohammad Azab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Azab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Azab. The network helps show where Mohammad Azab may publish in the future.

Co-authorship network of co-authors of Mohammad Azab

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Azab. A scholar is included among the top collaborators of Mohammad Azab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Azab. Mohammad Azab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Jahn, Nikolaus, Maral Saadati, Pierre Fenaux, et al.. (2023). Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 37(11). 2187–2196. 22 indexed citations

Rennert, Robert C., et al.. (2023). Modified Lateral Orbitotomy Approach to Lesions of the Orbital Apex, Superior Orbital Fissure, Cavernous Sinus, and Middle Cranial Fossa. Operative Neurosurgery. 24(5). 514–523. 12 indexed citations

Azab, Mohammad, Brandon Lucke‐Wold, Eric Panther, et al.. (2022). Case Series and Systematic Review of Electronic Scooter Crashes and Severe Traumatic Brain Injury. World Neurosurgery. 167. e184–e195. 8 indexed citations

Thota, Swapna, Aram Oganesian, Mohammad Azab, & Elizabeth A. Griffiths. (2021). Role of Cedazuridine/Decitabine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Future Oncology. 17(16). 2077–2087. 15 indexed citations

Ramsey, Haley E., Aram Oganesian, Agnieszka E. Gorska, et al.. (2020). Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. Targeted Oncology. 15(2). 231–240. 15 indexed citations

Garcia‐Manero, Guillermo, Elizabeth A. Griffiths, David P. Steensma, et al.. (2020). Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 136(6). 674–683. 145 indexed citations

Griffiths, Elizabeth A., Hagop M. Kantarjian, Casey L. O’Connell, et al.. (2019). Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients. Blood. 134(Supplement_1). 1319–1319.

Savona, Michael R., Olatoyosi Odenike, Philip C. Amrein, et al.. (2018). Pharmacokinetic- and Pharmacodynamic-Guided Phase 1 Study of an Oral Fixed-Dose Combination of Decitabine and the Cytidine Deaminase Inhibitor Cedazuridine in Myelodysplastic Syndromes. SSRN Electronic Journal. 1 indexed citations

Roboz, Gail J., Hagop M. Kantarjian, Karen Yee, et al.. (2017). Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 124(2). 325–334. 49 indexed citations

10.

Garcia‐Manero, Guillermo, Olatoyosi Odenike, Philip C. Amrein, et al.. (2016). Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study. Blood. 128(22). 114–114. 13 indexed citations

11.

Daver, Naval, Hagop M. Kantarjian, Gail J. Roboz, et al.. (2016). Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies. Blood. 128(22). 904–904. 10 indexed citations

12.

Issa, Jean‐Pierre J., Gail J. Roboz, David A. Rizzieri, et al.. (2015). Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. The Lancet Oncology. 16(9). 1099–1110. 210 indexed citations

13.

Gottipati, Srikanth, Shashank Rohatagi, Woonbok Chung, et al.. (2015). Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML). Blood. 126(23). 2594–2594. 1 indexed citations

14.

Savona, Michael R., Olatoyosi Odenike, Philip C. Amrein, et al.. (2015). Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS). Blood. 126(23). 1683–1683. 4 indexed citations

15.

Roboz, Gail J., Hagop M. Kantarjian, Patricia Kropf, et al.. (2015). Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy. Cancer Research. 75(15_Supplement). CT321–CT321. 3 indexed citations

16.

Mita, Monica, Michael S. Gordon, Lee S. Rosen, et al.. (2014). Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 74(1). 195–204. 25 indexed citations

17.

Ravandi, Farhad, Patricia Kropf, Karen Yee, et al.. (2014). Comparison of Efficacy and Safety of 5-Day and 10-Day Schedules of Sgi-110, a Novel Subcutaneous (Sc) Hypomethylating Agent (Hma), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml). Annals of Oncology. 25. iv328–iv328. 1 indexed citations

18.

Choy, Gavin, et al.. (2012). Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers. Cancer Chemotherapy and Pharmacology. 70(1). 183–190. 6 indexed citations

19.

Taverna, Pietro, et al.. (2010). SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation. Blood. 116(21). 1872–1872. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact